Shares of Glaukos Corporation (NYSE:GKOS) have been assigned a consensus recommendation of “Buy” from the nine analysts that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $46.00.

A number of equities research analysts have weighed in on GKOS shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 target price on shares of Glaukos in a report on Tuesday, November 7th. BMO Capital Markets reiterated a “buy” rating and issued a $45.00 target price on shares of Glaukos in a report on Wednesday, October 18th. Stephens reissued a “buy” rating and issued a $47.00 price objective on shares of Glaukos in a research note on Friday, September 15th. Piper Jaffray Companies reissued a “buy” rating and issued a $38.00 price objective on shares of Glaukos in a research note on Friday, September 15th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Glaukos in a research note on Thursday, September 14th.

In other news, CFO Joseph E. Gilliam acquired 2,100 shares of Glaukos stock in a transaction on Wednesday, November 22nd. The stock was purchased at an average price of $23.84 per share, with a total value of $50,064.00. Following the completion of the purchase, the chief financial officer now owns 102,100 shares of the company’s stock, valued at approximately $2,434,064. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 16.40% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. California Public Employees Retirement System boosted its position in shares of Glaukos by 10.5% during the second quarter. California Public Employees Retirement System now owns 8,400 shares of the medical instruments supplier’s stock valued at $348,000 after buying an additional 800 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Glaukos by 1.4% during the second quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock valued at $2,915,000 after buying an additional 994 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Glaukos by 93.1% during the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares during the last quarter. GSA Capital Partners LLP boosted its position in Glaukos by 3.7% in the second quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock worth $1,455,000 after purchasing an additional 1,237 shares during the last quarter. Finally, Navellier & Associates Inc boosted its position in Glaukos by 4.9% in the second quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock worth $1,381,000 after purchasing an additional 1,567 shares during the last quarter. 99.23% of the stock is currently owned by institutional investors.

Shares of Glaukos (GKOS) traded down $0.02 during mid-day trading on Thursday, reaching $25.53. The company’s stock had a trading volume of 407,300 shares, compared to its average volume of 640,192. The company has a market capitalization of $883.15, a P/E ratio of 212.92 and a beta of 1.02. Glaukos has a 1-year low of $23.44 and a 1-year high of $52.49.

Glaukos (NYSE:GKOS) last issued its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.06. The business had revenue of $40.41 million during the quarter, compared to the consensus estimate of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. The firm’s revenue for the quarter was up 36.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.03 earnings per share. sell-side analysts expect that Glaukos will post -0.03 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Glaukos Corporation (GKOS) Receives Consensus Recommendation of “Buy” from Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/07/glaukos-corporation-gkos-receives-consensus-recommendation-of-buy-from-brokerages.html.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.